Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients

Podobne zapisy

• Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
  od: Vera Aguilera, Jesus, i wsp.
  Wydane: (2020)
• T cell Bim levels reflect responses to anti–PD-1 cancer therapy
  od: Dronca, Roxana S., i wsp.
  Wydane: (2016)
• Personalized therapy for metastatic melanoma: could timing be everything?
  od: Dronca, Roxana S, i wsp.
  Wydane: (2012)
• Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era
  od: Youland, Ryan S., i wsp.
  Wydane: (2017)
• CX3CR1 identifies PD-1 therapy–responsive CD8(+) T cells that withstand chemotherapy during cancer chemoimmunotherapy
  od: Yan, Yiyi, i wsp.
  Wydane: (2018)